FDA Issues a Warning for Avastin – Again

The problems with the cancer drug Avastin are never ending. The FDA has issued a another warning about the drug’s dangers, this time involving ovarian failure, jaw necrosis (bone decay), blot clots and excessive bleeding.

We’ve written about Avastin as well, most recently last week in regard to its use as an injectable drug for macular dengeration, and about the risks it poses for breast cancer patients.

To explore just one of the reasons for the new warning, consider a study that found that 34% of women treated with Avastin during chemotherapy suffered ovarian failure, and most have not recovered their full fertility; only 2% given chemotherapy alone experienced ovarian failure.

Avastin was approved by the FDA in 2004 to treat nonsmall cell lung cancer and colorectal cancer in combination with chemotherapy. It received approval in 2008 to treat breast cancer, but that was revoked in 2010, and reconfirmed in June of this year.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Consumer Protection Updates, Personal Injury Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »